CoChat
Sign Up
Cited by 25Diabetes Treatment and ManagementHeart Failure Treatment and ManagementDiabetes Management and Research

Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies

Open access
Ahmad, Aftab, Sabbour, Hani·2024·Cardiovascular Diabetology
DOI 10.1186/s12933-024-02192-4PMC PMC10949729
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Randomized controlled trials and real-world studies suggest that combination therapy with sodium–glucose transport protein 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is associated with improvement in fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), systolic blood pressure (SBP), body mass index (BMI), and total cholesterol levels. However, a systematic review of available real-world evidence may facilitate clinical decision-making in the real-world scenario. This meta-analysis assessed the safety and effectiveness of combinations of SGLT2is + GLP-1RAs with a focus on their cardioprotective effects along with glucose-lowering ability in patients with type 2 diabetes mellitus (T2DM) in a real-world setting. Methods: Electronic searches were performed in the PubMed/MEDLINE, PROQuest, Scopus, CINAHL, and Google Scholar databases. Qualitative analyses and meta-analyses were performed using the Joanna Briggs Institute SUMARI software package and Review Manager v5.4, respectively. Results: The initial database search yielded 1445 articles; of these, 13 were included in this study. The analyses indicated that SGLT2is + GLP-1RAs combinations were associated with significantly lower all-cause mortality when compared with individual therapies (odds ratio [95% confidence interval [CI] 0.49 [0.41, 0.60]; p < 0.00001). Significant reductions in BMI (− 1.71 [− 2.74, − 0.67]; p = 0.001), SBP (− 6.35 [− 10.17, − 2.53]; p = 0.001), HbA1c levels (− 1.48 [− 1.75, − 1.21]; p < 0.00001), and FPG (− 2.27 [− 2.78, − 1.76]; p < 0.00001) were associated with the simultaneous administration of the combination. Changes in total cholesterol levels and differences between simultaneous and sequential combination therapies for this outcome were not significant. Conclusion: This systematic review and meta-analysis based on real-world data suggests that the combination of SGLT2is + GLP-1RAs is associated with lower all-cause mortality and favorable improvements in cardiovascular, renal, and glycemic measurements. The findings drive a call-to–action to incorporate this combination early and simultaneously in managing T2DM patients and achieve potential cardiovascular benefits and renal protection. Graphical Abstract:

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12933-024-02192-4

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The combination of GLP-1 receptor agonists and SGLT2 inhibitors is associated with a lower risk of major adverse cardiovascular events and serious kidney disease events compared with either drug class alone.

    “The authors concluded that the combination of both drug classes was associated with a lower risk of MACE and serious kidney disease events compared with either drug class alone.”

    From Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial (2024) · cites this paper as [11]

    The Introduction and Discussion report lower MACE risk with combination therapy than with monotherapy, although the paper attributes that finding to earlier studies rather than to its own pooled analysis. The Results (Renal outcomes; page not provided) report eGFR and albuminuria findings, but do not establish a lower risk of serious kidney disease events compared with either drug class alone. Thus the claimed conclusion is only partly supported. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 63

  1. [2]Padhi S Nayak AK Behera A Type II diabetes mellitus: a review on recent drug based therapeutics Biomed Pharmacother 2020 131 110708 10.1016/j.biopha.2020.110708 32927252 · DOI · Paper page
  2. [3]Palmer SC Tendal B Mustafa RA Vandvik PO Li S Hao Q Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials BMJ 2021 10.1136/bmj.m4573 33441402 PMC7804890 · DOI · Paper page
  3. [5]Marilly E Cottin J Cabrera N Cornu C Boussageon R Moulin P SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits Diabetologia 2022 65 2000 2010 10.1007/s00125-022-05773-8 35925319 · DOI
  4. [6]Lee MMY Kristensen SL Gerstein HC McMurray JJV Sattar N Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial Diabetes Metab Syndr 2022 16 102382 10.1016/j.dsx.2021.102382 35030451 · DOI · Paper page
  5. [8]Zou C-Y Liu X-K Sang Y-Q Wang B Liang J Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes Medicine (Baltimore) 2019 98 e18245 10.1097/MD.0000000000018245 31804352 PMC6919451 · DOI
  6. [9]Teo YH Teo YN Syn NL Kow CS Yoong CSY Tan BYQ Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials J Am Heart Assoc 2021 10 e019463 10.1161/JAHA.120.019463 33625242 PMC8174267 · DOI
  7. [11]Ali MU Mancini GBJ Fitzpatrick-Lewis D Lewis R Jovkovic M Zieroth S The Effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiorenal outcomes: systematic review and meta-analysis Can J Cardiol 2022 38 1201 1210 10.1016/j.cjca.2022.05.011 35961756 · DOI
  8. [12]McGuire DK Shih WJ Cosentino F Charbonnel B Cherney DZI Dagogo-Jack S Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis JAMA Cardiol 2021 6 148 10.1001/jamacardio.2020.4511 33031522 PMC7542529 · DOI · Paper page
  9. [13]Guo M Gu J Teng F Chen J Ma X Chen Q The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis Endocrine 2020 67 294 304 10.1007/s12020-019-02175-6 31900793 · DOI
  10. [14]Mantsiou C Karagiannis T Kakotrichi P Malandris K Avgerinos I Liakos A Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis Diabetes Obesity Metabolism 2020 22 1857 1868 10.1111/dom.14108 32476254 · DOI · Paper page
  11. [15]Li C Luo J Jiang M Wang K The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis Front Pharmacol 2022 13 838277 10.3389/fphar.2022.838277/full 35185588 PMC8854770 · DOI
  12. [16]Patoulias D Stavropoulos K Imprialos K Katsimardou A Kalogirou M-S Koutsampasopoulos K Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials Diabetes Res Clin Pract 2019 158 107927 10.1016/j.diabres.2019.107927 31733280 · DOI
  13. [17]Lopez PD Bhatia K Bohra C Mahmood K Baruch L Eng C Benefits of adding glucagon-like peptide 1 receptor agonists to sodium-glucose co-transporter 2 inhibitors in diabetic patients with atherosclerotic disease and heart failure Am J Cardiol 2022 181 87 93 10.1016/j.amjcard.2022.07.012 35963825 · DOI
  14. [18]Du L Qin J Wang D Zhao Y Xu N Wu C Meta-analysis assessing the effectiveness of SGLT2i+GLP1RA combination therapy versus monotherapy on cardiovascular and cerebrovascular outcomes in diabetic patients Front Physiol 2022 10.3389/fphys.2022.1028486 36419835 PMC9676496 · DOI
  15. [19]Clark J Glasziou P Del Mar C Bannach-Brown A Stehlik P Scott AM A full systematic review was completed in 2 weeks using automation tools: a case study J Clin Epidemiol 2020 121 81 90 10.1016/j.jclinepi.2020.01.008 32004673 · DOI · Paper page
  16. [20]Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: Systematic reviews of etiology and risk. JBI manual for evidence synthesis; 2020. https://synthesismanual.jbi.global
  17. [22]Arévalo-Lorido JC Gómez JC Huelgas RG De Lucas DG Polo LM Aguilar JMV Lowering blood pressure with the combination of a sodium-glucose cotransporter 2 inhibitor and a glucagon-like peptide-1 receptor agonist in type 2 diabetic patients: a clinical evidence High Blood Press Cardiovasc Prev 2018 25 417 420 10.1007/s40292-018-0280-1 30251110 · DOI
  18. [23]Berkovic MC Bilic-Curcic I Bozek T Mahecic DH Majanovic SK Canecki-Varzic S Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination—are we exploiting their full potential in a real life setting? WJD 2020 11 540 552 10.4239/wjd.v11.i11.540 33269065 PMC7672794 · DOI
  19. [24]Bhattacharyya S Clinical effectiveness of combination therapy with dulaglutide, SGLT2 inhibitor and metformin with or without insulin in Indian adults with type 2 diabetes: a real-world retrospective study Clinical Diabetology 2020 9 233 238 10.5603/DK.2020.0026 · DOI
  20. [25]Deol H Lekkakou L Viswanath AK Pappachan JM Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience Endocrine 2017 55 173 178 10.1007/s12020-016-1125-0 27696231 · DOI
  21. [26]Díaz-Trastoy O Villar-Taibo R Sifontes-Dubón M Mozo-Peñalver H Bernabeu-Morón I Cabezas-Agrícola JM GLP1 receptor agonist and SGLT2 inhibitor combination: an effective approach in real-world clinical practice Clin Ther 2020 42 e1 12 10.1016/j.clinthera.2019.12.012 32005534 · DOI
  22. [27]Carretero Gómez J Arévalo Lorido JC Gómez Huelgas R García De Lucas D Mateos Polo L Varela Aguilar JM Combination therapy with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes: a real-world evidence study Can J Diabetes 2019 43 186 192 10.1016/j.jcjd.2018.09.001 30415909 · DOI
  23. [28]Carretero Gómez J Ena J Seguí Ripoll JM Carrasco-Sanchez FJ Gómez Huelgas R Mateos Polo L Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents Int J Clin Pract 2020 10.1111/ijcp.13586 32533906 · DOI
  24. [29]Goncalves E Bell DSH Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: sequential or simultaneous start? Diabetes Obes Metab 2017 19 909 911 10.1111/dom.12897 28176440 · DOI
  25. [30]Jensen MH Kjolby M Hejlesen O Jakobsen PE Vestergaard P Risk of major adverse cardiovascular events, severe hypoglycemia, and all-cause mortality for widely used antihyperglycemic dual and triple therapies for type 2 diabetes management: a cohort study of all danish users Diabetes Care 2020 43 1209 1218 10.2337/dc19-2535 32238426 · DOI
  26. [31]Kim HS Yoon T Jung CH Park J-Y Lee WJ Clinical efficacy of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist combination therapy in type 2 diabetes mellitus: real-world study Diabetes Metab J 2022 46 658 662 10.4093/dmj.2021.0232 34743486 PMC9353570 · DOI
  27. [32]Gorgojo-Martínez JJ Serrano-Moreno C Sanz-Velasco A Feo-Ortega G Almodóvar-Ruiz F Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes Nutr Metab Cardiovasc Dis 2017 27 129 137 10.1016/j.numecd.2016.11.007 28077257 · DOI
  28. [33]Riley DR Essa H Austin P Preston F Kargbo I Ibarburu GH All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes Diabetes Obesity Metabolism 2023 25 2897 2909 10.1111/dom.15185 37385958 · DOI
  29. [34]Saroka RM Kane MP Busch RS Watsky J Hamilton RA SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM Endocr Pract 2015 21 1315 1322 10.4158/EP15877.OR 26307900 · DOI
  30. [35]Wagdy K The EMPEROR-reduced trial: SGLT2 inhibitors for heart failure get more support Glob Cardiol Sci Pract 2020 2020 e202031 33598491 PMC7868098
  31. [36]Wagdy K Nagy S EMPEROR-preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction Glob Cardiol Sci Pract 2021 2021 e202117 34805375 PMC8587377
  32. [38]Neal B Perkovic V Mahaffey KW de Zeeuw D Fulcher G Erondu N Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 2017 377 644 657 10.1056/NEJMoa1611925 28605608 · DOI · Paper page
  33. [39]Wiviott SD Raz I Bonaca MP Mosenzon O Kato ET Cahn A Dapagliflozin and cardiovascular outcomes in type 2 diabetes N Engl J Med 2019 380 347 357 10.1056/NEJMoa1812389 30415602 · DOI · Paper page
  34. [40]Hernandez AF Green JB Janmohamed S D'Agostino RB Granger CB Jones NP Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Lancet (London, England) 2018 392 1519 1529 10.1016/S0140-6736(18)32261-X 30291013 · DOI · Paper page
  35. [41]Gerstein HC Colhoun HM Dagenais GR Diaz R Lakshmanan M Pais P Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial The Lancet 2019 394 121 130 10.1016/S0140-6736(19)31149-3 31189511 · DOI · Paper page
  36. [42]Verma S Bhatt DL Bain SC Buse JB Mann JFE Marso SP Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease: results of the LEADER trial Circulation 2018 137 2179 2183 10.1161/CIRCULATIONAHA.118.033898 29760228 · DOI · Paper page
  37. [45]Husain M Birkenfeld AL Donsmark M Dungan K Eliaschewitz FG Franco DR Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes N Engl J Med 2019 381 841 851 10.1056/NEJMoa1901118 31185157 · DOI · Paper page
  38. [47]Dave CV Kim SC Goldfine AB Glynn RJ Tong A Patorno E Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of sglt2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy Circulation 2021 143 770 779 10.1161/CIRCULATIONAHA.120.047965 33302723 PMC7902404 · DOI
  39. [48]Singh AK Singh R Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes WJC 2022 14 329 342 10.4330/wjc.v14.i6.329 35979179 PMC9258221 · DOI
  40. [49]Mone P Lombardi A Kansakar U Varzideh F Jankauskas SS Pansini A Empagliflozin improves the MicroRNA signature of endothelial dysfunction in patients with heart failure with preserved ejection fraction and diabetes J Pharmacol Exp Ther 2023 384 116 122 10.1124/jpet.121.001251 36549862 PMC9827502 · DOI
  41. [50]Mone P Varzideh F Jankauskas SS Pansini A Lombardi A Frullone S SGLT2 inhibition via empagliflozin improves endothelial function and reduces mitochondrial oxidative stress: insights from frail hypertensive and diabetic patients Hypertension 2022 79 1633 1643 10.1161/HYPERTENSIONAHA.122.19586 35703100 PMC9642044 · DOI
  42. [51]Ikonomidis I Pavlidis G Thymis J Birba D Kalogeris A Kousathana F Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and myocardial work index in patients with type 2 diabetes mellitus after 12-month treatment JAHA 2020 9 e015716 10.1161/JAHA.119.015716 32326806 PMC7428590 · DOI · Paper page
  43. [52]Jensen DM Skovsted GF Bonde MFB Bentzon JF Rolin B Franck G Semaglutide treatment attenuates vessel remodelling in ApoE-/- mice following vascular injury and blood flow perturbation Atheroscler Plus 2022 49 32 41 10.1016/j.athplu.2022.05.004 36644202 PMC9833261 · DOI
  44. [53]Gourdy P Darmon P Dievart F Halimi J-M Guerci B Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM) Cardiovasc Diabetol 2023 22 79 10.1186/s12933-023-01798-4 37005640 PMC10067319 · DOI
  45. [54]Busch RS Kane MP Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes Postgrad Med 2017 129 686 697 10.1080/00325481.2017.1342509 28657399 · DOI
  46. [55]Laiteerapong N Ham SA Gao Y Moffet HH Liu JY Huang ES The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the diabetes & aging study) Diabetes Care 2019 42 416 426 10.2337/dc17-1144 30104301 PMC6385699 · DOI · Paper page
  47. [56]Koliaki C Doupis J Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus Diab Ther 2011 2 101 121 10.1007/s13300-011-0002-3 PMC3144767 22127804 · DOI · Paper page
  48. [57]Janež A Fioretto P SGLT2 inhibitors and the clinical implications of associated weight loss in type 2 diabetes: a narrative review Diabetes Ther 2021 12 2249 2261 10.1007/s13300-021-01104-z 34244976 PMC8342745 · DOI
  49. [58]Liakos CI Papadopoulos DP Sanidas EA Markou MI Hatziagelaki EE Grassos CA Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors) Am J Cardiovasc Drugs 2021 21 123 137 10.1007/s40256-020-00423-z 32780214 · DOI · Paper page
  50. [59]Dutka M Bobiński R Ulman-Włodarz I Hajduga M Bujok J Pająk C Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure Heart Fail Rev 2021 26 603 622 10.1007/s10741-020-10041-1 33150520 PMC8024236 · DOI
  51. [60]Granata A Maccarrone R Anzaldi M Leonardi G Pesce F Amico F GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art Clin Kidney J 2022 15 1657 1665 10.1093/ckj/sfac069 36003669 PMC9394722 · DOI · Paper page
  52. [61]Rossing P Baeres FMM Bakris G Bosch-Traberg H Gislum M Gough SCL The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease Nephrol Dial Transplant 2023 38 2041 2051 10.1093/ndt/gfad009 36651820 PMC10469096 · DOI · Paper page
  53. [62]Márquez DF Ruiz-Hurtado G Segura J Ruilope L Microalbuminuria and cardiorenal risk: old and new evidence in different populations F1000Res 2019 10.12688/f1000research.17212.1 31583081 PMC6758838 · DOI
  54. [64]Jeong SJ Lee SE Shin DH Park IB Lee HS Kim K-A Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study BMC Nephrol 2021 22 177 10.1186/s12882-021-02381-3 33990175 PMC8122538 · DOI
  55. [65]Mancini GBJ O’Meara E Zieroth S Bernier M Cheng AYY Cherney DZI Canadian cardiovascular society guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults Can J Cardiol 2022 38 1153 1167 10.1016/j.cjca.2022.04.029 35961754 · DOI
  56. [66]Rowlands J Heng J Newsholme P Carlessi R Pleiotropic effects of GLP-1 and analogs on cell signaling, metabolism, and function Front Endocrinol 2018 9 672 10.3389/fendo.2018.00672/full PMC6266510 30532733 · DOI
  57. [67]Das SR Everett BM Birtcher KK Brown JM Januzzi JL Kalyani RR Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes J Am Coll Cardiol 2020 76 1117 1145 10.1016/j.jacc.2020.05.037 32771263 PMC7545583 · DOI · Paper page
  58. [69]Cosentino F Grant PJ Aboyans V Bailey CJ Ceriello A Delgado V 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD Eur Heart J 2020 41 255 323 10.1093/eurheartj/ehz486 31497854 · DOI · Paper page
  59. [70]Houlden RL Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada Can J Diabetes 2018 42 S1 5 10.1016/j.jcjd.2017.10.001 24070926 · DOI
  60. [71]Korayem GB Alshaya OA Alghamdi AA Alanazi SS Almutib RT Alsaileek M The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study Front Public Health 2022 10.3389/fpubh.2022.1031306 36408008 PMC9673169 · DOI
  61. [74]Jabbour SA Frías JP Guja C Hardy E Ahmed A Öhman P Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study Diabetes Obes Metab 2018 20 1515 1519 10.1111/dom.13206 29316164 PMC5969082 · DOI
  62. [76]Vaduganathan M Sathiyakumar V Singh A McCarthy CP Qamar A Januzzi JL Prescriber patterns of SGLT2i after expansions of U.S. food and drug administration labeling J Am College Cardiol 2018 72 3370 3372 10.1016/j.jacc.2018.08.2202 30409566 · DOI
  63. [77]DeFronzo RA Combination therapy with GLP -1 receptor agonist and SGLT2 inhibitor Diabetes Obes Metab 2017 19 1353 1362 10.1111/dom.12982 28432726 PMC5643008 · DOI · Paper page

Cited by

Sorted by citations

Authors
Ahmad, A., & Sabbour, H.
Affiliations
  • Imperial College London Diabetes Centre (AE)
  • Brown University (US)
Corresponding author
Ahmad, Aftab
ORCID
Venue
Cardiovascular Diabetology
Publisher
Springer Science and Business Media LLC
Published
2024-03-18
Volume
23
Issue
1
Pages
99-99
ISSN
1475-2840 (ISSN-L)
DOI
10.1186/s12933-024-02192-4
PMC
PMC10949729
OpenAlex
W4392908514
Cited by
25
References
14
Citations by year
2026: 5 · 2025: 12 · 2024: 8
FWCI
1.47
Type
journal article
Language
en
Update notices
correction (2024-06-01)
Open access
Licence
Locations
  • Cardiovascular Diabetology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, SGLT2 inhibitors, GLP-1 receptor agonists, combination therapy, real-world evidence, all-cause mortality, glycemic control, HbA1c, fasting blood glucose, blood pressure, body mass index, cholesterol, cardioprotection, drug safety, drug effectiveness, antidiabetic drugs
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Blood Glucose, Cholesterol, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review